Longboard Pharmaceuticals

Longboard Pharmaceuticals :
Focused on developing a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. The company is also evaluating LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, in development for the potential treatment of multiple neurological diseases, and LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, in development for the potential treatment of central nervous system (CNS) diseases and disorders.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Listing
Public, USA
Market Cap
100MM - 500MM
Website:
Address:
4275 Executive Square
Suite 950
La Jolla, CA 92037
United States
Suite 950
La Jolla, CA 92037
United States
More info:
My account:
Company Participants at Solebury 1x1 Management Access Event 2023
- Kevin Lind, President and CEO
Top 10 Holders of Longboard Pharmaceuticals, Inc.
Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
---|---|---|---|---|---|
Fidelity Management & Research Co. LLC | 12.50 | 2,567,948 | 14.28 | 13F | 6/30/23 |
Cormorant Asset Management LP | 11.45 | 2,353,141 | 13.08 | 13F | 6/30/23 |
T Rowe Price Associates, Inc. (13F Subfiler) | 8.22 | 1,688,156 | 9.39 | 13F | 6/30/23 |
T. Rowe Price Associates, Inc. (Investment Management) | 7.26 | 1,492,777 | 8.30 | Funds | 6/30/23 |
Fidelity Investments Canada ULC | 6.94 | 1,427,422 | 7.94 | Funds | 7/31/23 |
HBM Partners AG (Investment Management) | 9.90 | 1,345,009 | 7.48 | Stakes | 12/31/22 |
Farallon Capital Management LLC | 4.87 | 1,000,000 | 5.56 | 13F | 6/30/23 |
Point72 Asset Management LP | 4.01 | 825,000 | 4.59 | 13F | 6/30/23 |
Prosight Management LP | 3.58 | 734,897 | 4.09 | 13F | 6/30/23 |
Vanguard Group, Inc. (Subfiler) | 3.16 | 650,052 | 3.61 | 13F | 6/30/23 |
Top 10 Holders of Longboard Pharmaceuticals, Inc.
Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
---|---|---|---|---|---|
Cormorant Asset Management LP | 22.65 | 822,164 | 0.00 | Stakes | 12/31/22 |
Farallon Capital Management LLC | 16.74 | 607,417 | 0.00 | Stakes | 12/31/22 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.